Wiki source code of Neurodiagnoses
Version 22.1 by manuelmenendez on 2025/01/29 18:44
Hide last authors
| author | version | line-number | content |
|---|---|---|---|
 |
1.1 | 1 | (% class="jumbotron" %) |
| 2 | ((( | ||
| 3 | (% class="container" %) | ||
| 4 | ((( | ||
| |
17.1 | 5 | = //A new tridimensional diagnostic framework for neurodegenerative diseases// = |
| |
1.1 | 6 | |
| |
19.1 | 7 | This project is focused on developing a novel nosological and diagnostic framework for neurodegenerative diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. |
| |
6.1 | 8 | We aim to create a structured, interpretable, and scalable diagnostic tool. |
| |
1.1 | 9 | ))) |
| 10 | ))) | ||
| 11 | |||
| 12 | (% class="row" %) | ||
| 13 | ((( | ||
| 14 | (% class="col-xs-12 col-sm-8" %) | ||
| 15 | ((( | ||
| |
6.1 | 16 | = What is this about and what can I find here? = |
| |
1.1 | 17 | |
| |
9.1 | 18 | == **Overview** == |
| |
6.1 | 19 | |
| |
17.1 | 20 | The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDD) are classified by focusing on: |
| |
6.1 | 21 | |
| |
16.1 | 22 | * **Axis 1**: Etiology (genetic or other causes of diseases). |
| 23 | * **Axis 2**: Molecular Markers (biomarkers). | ||
| |
6.1 | 24 | * **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). |
| 25 | |||
| |
14.1 | 26 | [[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] |
| 27 | |||
| |
15.1 | 28 | |
| |
6.1 | 29 | This methodology enables: |
| 30 | |||
| 31 | * Greater precision in diagnosis. | ||
| 32 | * Integration of incomplete datasets using AI-driven probabilistic modeling. | ||
| 33 | * Stratification of patients for personalized treatment. | ||
| 34 | |||
| |
9.1 | 35 | == **Diagnostic Axes** == |
| |
6.1 | 36 | |
| 37 | * ((( | ||
| 38 | **Axis 1: Etiology** | ||
| 39 | |||
| 40 | * //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. | ||
| 41 | * //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. | ||
| 42 | * //Tests//: Genetic testing, lifestyle and cardiovascular screening. | ||
| 43 | ))) | ||
| 44 | * ((( | ||
| 45 | **Axis 2: Molecular Markers** | ||
| 46 | |||
| 47 | * //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. | ||
| 48 | * //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. | ||
| 49 | * //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). | ||
| 50 | ))) | ||
| 51 | * ((( | ||
| 52 | **Axis 3: Neuroanatomoclinical** | ||
| 53 | |||
| 54 | * //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments. | ||
| 55 | * //Examples//: Hippocampal atrophy correlating with memory deficits. | ||
| 56 | * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. | ||
| 57 | ))) | ||
| 58 | |||
| |
9.1 | 59 | == **Applications** == |
| |
6.1 | 60 | |
| 61 | This system enhances: | ||
| 62 | |||
| |
7.2 | 63 | * **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials. |
| |
6.1 | 64 | * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. |
| 65 | |||
| |
5.1 | 66 | == Who has access? == |
| |
1.1 | 67 | |
| |
4.2 | 68 | We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! |
| |
4.4 | 69 | |
| |
10.1 | 70 | == How to Contribute == |
| |
4.4 | 71 | |
| 72 | * Access the `/docs` folder for guidelines. | ||
| 73 | * Use `/code` for the latest AI pipelines. | ||
| 74 | * Share feedback and ideas in the wiki discussion pages. | ||
| |
5.1 | 75 | |
| |
10.1 | 76 | == Key Objectives == |
| |
5.1 | 77 | |
| 78 | * Develop interpretable AI models for diagnosis and progression tracking. | ||
| 79 | * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. | ||
| 80 | * Foster collaboration among neuroscientists, AI researchers, and clinicians. | ||
| |
1.1 | 81 | ))) |
| 82 | |||
| 83 | |||
| 84 | (% class="col-xs-12 col-sm-4" %) | ||
| 85 | ((( | ||
| 86 | {{box title="**Contents**"}} | ||
| 87 | {{toc/}} | ||
| 88 | {{/box}} | ||
| 89 | |||
| |
10.1 | 90 | == Main contents == |
| |
4.4 | 91 | |
| |
5.1 | 92 | * `/docs`: Documentation and contribution guidelines. |
| 93 | * `/code`: Machine learning pipelines and scripts. | ||
| 94 | * `/data`: Sample datasets for testing. | ||
| 95 | * `/outputs`: Generated models, visualizations, and reports. | ||
| |
21.1 | 96 | * [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]] |
| 97 | * [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]] | ||
| |
22.1 | 98 | * [[to-do-list>>to-do-list]] |
| |
1.1 | 99 | ))) |
| 100 | ))) |